Smith et al. (2023) — PULSAR trial 2-year outcomes
10.1056/NEJMoa2308635
Aflibercept 8mg maintained visual gains through 96 weeks.
Find the claims in your draft that cite nothing.
The PULSAR trial randomized 1009 eyes to aflibercept 8mg versus 2mg. Cost-effectiveness at current US pricing is neutral versus the 2mg regimen. Best-corrected visual acuity gains were maintained through week 96 without new safety signals.
How it works
Evidence, not assertion
Every claim is checked against the published literature — not a language model's memory. Deep checks argue a case for and against before ruling.
Six-state verdicts
From strongly challenged to strongly supported, plus a separate inconclusive when the evidence can't decide. Never a bare true or false.
In your draft, in context
Claims stay highlighted where they sit. The papers for and against are one click away.